Choline salt of phenanthridinone derivative

Choline salts of phenanthridinone derivatives address the limitations of current anti-coronavirus drugs by providing enhanced antiviral activity and solubility, offering a promising new treatment for SARS-CoV-2 and related coronaviruses with improved safety and efficacy.

WO2024237331A1PCT designated stage expired Publication Date: 2024-11-21ONCOLYS BIOPHARMA INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018284
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current anti-coronavirus drugs, such as molnupiravir and Paxlovid, have side effects and compatibility issues when used in combination with other medications, highlighting the need for new drugs with selective and potent antiviral effects against SARS-CoV-2.

Method used

Development of choline salts of phenanthridinone derivatives, which exhibit improved anti-coronavirus efficacy and solubility, specifically targeting SARS-CoV-2, with enhanced pharmacokinetic properties and reduced side effects.

Benefits of technology

The choline salts demonstrate superior antiviral activity against SARS-CoV-2, COVID-19, SARS, and MERS, with improved solubility and reduced toxicity, offering a potential alternative to existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018284_21112024_PF_FP_ABST
    Figure JP2024018284_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a salt of a phenanthridinone derivative having an excellent anti-coronavirus effect and excellent solubility. Also provided are crystals of the salt. Provided specifically are a choline salt of a compound represented by the formula (I), crystals of the salt, and the use of the salt or crystals. [In the formula, R1 is C1-C8 alkyl or the like; R2-R9 are each independently a hydrogen, a halogen, a hydroxyl, NH2, Q-(C1-C8 alkyl) (Q is O, NH or S) or the like; and at least one of R7 and R8 is NH2 or NH(R10) (R10 is an optionally substituted C1-C8 alkyl or the like). ]
Need to check novelty before this filing date? Find Prior Art

Description

Choline salts of phenanthridinone derivatives

[0001] The present invention relates to choline salts of phenanthridinone derivatives that are useful as anti-coronavirus agents.

[0002] Coronaviruses are viruses that originally cause cold symptoms in humans. Four types of coronaviruses are known, and these viruses are responsible for 10-15% of colds. In addition, coronaviruses that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which have high fatality rates, are known to date. SARS has affected approximately 8,000 people with a fatality rate of approximately 10%, while MERS has affected approximately 2,500 people with a fatality rate of approximately 35%. Coronaviruses are enveloped, positive-strand RNA viruses with a diameter of approximately 100 nm. SARS-CoV is classified as a type 2 pathogen, and MERS-CoV as a type 3 pathogen.

[0003] Currently, various antibody drugs targeting the spike protein on the surface of SARS-CoV-2 and remdesivir, a drug repurposed from an anti-Ebola drug, are being used as therapeutic agents. Other approved anti-SARS-CoV-2 drugs include molnupiravir, developed as an anti-influenza drug, and the newly developed paxlobid (Paquilobid). Molnupiravir's mechanism of action is believed to be to inhibit the viral RNA-dependent RNA polymerase enzyme and induce errors during viral RNA replication. Paxlobid is a combination drug containing the low-molecular-weight compound nilmatrervir, which inhibits the function of the main protease required for viral replication, and ritonavir, which acts as a booster to maintain its blood concentration. However, these drugs have several drawbacks, including side effects such as teratogenicity and problems with combination therapy with other drugs. Therefore, it is extremely important to identify and develop novel drugs with selective and potent antiviral effects against SARS-CoV-2.

[0004] The present inventors have found that certain phenanthridinone derivatives have anti-SARS-CoV-2 activity and have filed a patent application (Patent Document 1).

[0005] International Publication No. 2021 / 235392

[0006] An object of the present invention is to provide a salt of a phenanthridinone derivative and a crystal thereof that have an excellent anti-coronavirus effect and excellent solubility.

[0007] The present inventors have succeeded in synthesizing a novel phenanthridinone derivative having a more excellent anti-coronavirus effect than the phenanthridinone derivative described in Patent Document 1, and have filed a patent application (PCT / JP2022 / 042332). As a result of further research, the present inventors have found that the solubility of the novel phenanthridinone derivative can be improved by converting it into a choline salt, which has led to the completion of the present invention.

[0008] That is, the gist of the present invention is as follows: (1) Formula (I): [In the formula, R 1is C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl, heteroaryl, and heteroarylalkyl, each of which is independently unsubstituted or substituted with one or more halogen, hydroxyl, NH2, NO2, C(O)Z (wherein Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2, or NH-(C1-C8 alkyl)); alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl), or Q-(heteroarylalkyl), wherein Q is O, NH, or S; R 2 ~R 9are each independently hydrogen, halogen, hydroxyl, NH2, NO2, OSO3H, C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2, or NH-(C1-C8 alkyl)), NH-C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2 or NH-(C1-C8 alkyl)), NH-C(NH)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2 or NH-(C1-C8 alkyl)), N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, arylalkyl, or heterocyclyl), NH(R 10 ) (R 10is C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, arylalkyl, or heterocyclyl), Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl), and Q-(heteroarylalkyl) (Q is O, NH, or S), as well as C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl , aryl, arylalkyl, arylalkenyl, heteroaryl, and heteroarylalkyl (each of the foregoing groups is independently unsubstituted or substituted with one or more halogen, hydroxyl, NH, NO, C(O)Z (wherein Z is hydrogen, hydroxyl, C-C alkyl, C-C alkenyl, C-C alkynyl, C-C cycloalkyl, C-C cycloalkenyl, C-C cycloalkynyl, heterocyclyl, NH, or NH-(C-C alkyl)), NH-C(O)Z (wherein Z is hydrogen, hydroxyl, C-C alkyl, C-C alkenyl, C-C alkynyl, C-C cycloalkyl, C-C cycloalkenyl, C-C cycloalkynyl, heterocyclyl, NH, or NH-(C-C alkyl)), N(R 10 )(R 11 ) (R 10 and R 11are each independently C1 to C8 alkyl, C2 to C8 alkenyl, C2 to C8 alkynyl, C3 to C6 cycloalkyl, C3 to C6 cycloalkenyl, C4 to C6 cycloalkynyl, arylalkyl, or heterocyclyl), C1 to C8 alkyl, C2 to C8 alkenyl, C2 to C8 alkynyl, C3 to C6 cycloalkyl, C3 to C6 cycloalkenyl, C4 to C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl, heteroaryl Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl), or Q-(heteroarylalkyl), where Q is O, NH, or S; 2 ~R 5any two of these, together with the carbon atoms on the phenanthridine ring to which they are attached, form a cycloalkyl, heterocyclyl, or aryl fused to the phenanthridine ring (the cycloalkyl, heterocyclyl, or aryl fused to the phenanthridine ring are each independently unsubstituted or substituted with one or more of halogen, hydroxyl, NH, NO, C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH, or NH-(C1-C8 alkyl)), C1-C8 alkyl, C2-C Q-C6 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl), or Q-(heteroarylalkyl) where Q is O, NH, or S; 7 and R 8 at least one of the above is NH2, NH-C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2, or NH-(C1-C8 alkyl)), NH-C(NH)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2, or NH-(C1-C8 alkyl)), N(R 10 )(R 11 ) (R 10 and R 11are each independently C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, arylalkyl, or heterocyclyl) or NH(R 10 ) (R 10 is C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, arylalkyl, or heterocyclyl, each of which is independently unsubstituted or substituted with one or more of halogen, hydroxyl, NH2, C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkynyl, arylalkyl, or heterocyclyl). C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2 or NH-(C1-C8 alkyl)), NH-C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2 or NH-(C1-C8 alkyl)), N(R 10 )(R 11 ) (R 10 and R 11are each independently C1 to C8 alkyl, C2 to C8 alkenyl, C2 to C8 alkynyl, C3 to C6 cycloalkyl, C3 to C6 cycloalkenyl, C4 to C6 cycloalkynyl, arylalkyl, or heterocyclyl), C1 to C8 alkyl, C2 to C8 alkenyl, C2 to C8 alkynyl, C3 to C6 cycloalkyl, C3 to C6 cycloalkenyl, C4 to C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl (2) a choline salt of a compound represented by the formula: R, heteroaryl, heteroarylalkyl, Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl), or Q-(heteroarylalkyl) (Q is substituted with O, NH, or S). 7 and R 8 at least one of NH2, NH-C(O)Z (wherein Z is C1-C8 alkyl, heterocyclyl, or NH-(C1-C8 alkyl), which groups are unsubstituted or substituted by one or more hydroxyl or NH2), N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1-C8 alkyl or arylalkyl, which groups are unsubstituted or substituted by one or more hydroxyl, O—(C1-C8 alkyl), NH2, N(CH3)2, or CONH2) or NH(R 10 ) (R 10 (3) The choline salt according to (1) above, wherein R is C1-C8 alkyl, arylalkyl, or heterocyclyl, which is unsubstituted or substituted with one or more hydroxyl, O—(C1-C8 alkyl), NH, N(CH), or CONH. 8 is NH(R 10 ) (R 10(4) The choline salt according to (1), wherein R is C2-C5 alkyl substituted with one or two hydroxyl groups, or NH—C(O)Z (wherein Z is heterocyclyl substituted with one hydroxyl group). 1 (5) The choline salt according to any one of (1) to (3), wherein R is a C3 to C7 alkyl. 1 (6) The choline salt according to any one of (1) to (3), wherein R is a C4 alkyl. 3 (7) The choline salt according to any one of (1) to (5), wherein is 1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl. (8) A choline salt of a compound represented by the formula: (8) A crystal of the choline salt according to any one of (1) to (7) above. (9) The crystal according to (8) above, which has at least three peaks selected from 8.8, 14.6, 19.6, 23.8, and 27.0 at 2θ±0.2 in powder X-ray analysis. (10) The crystal according to (8) or (9) above, which exhibits an onset of melting at 210±1°C or 216±1°C in differential scanning calorimetry. (11) The crystal according to any one of (8) to (10) above, which is crystalline form I, IV, or XII. (12) The crystal according to (11) above, which is crystalline form XII, is a hydrate. (13) A method for producing the crystal according to any one of (8) to (12) above, which comprises the steps of dissolving the choline salt according to any one of (1) to (7) above in ethanol or 1-butanol, and adding n-heptane to the obtained solution to crystallize it. (14) A method for producing the crystal according to any one of (8) to (12), comprising the steps of dissolving the free form of the compound represented by formula (I) according to (1) in 1-butanol, adding an aqueous solution of choline, and adding n-heptane to the resulting solution to crystallize it. (15) A pharmaceutical composition containing, as an active ingredient, the choline salt according to any one of (1) to (7) or the crystal according to any one of (8) to (12). (16) An anti-coronavirus drug containing, as an active ingredient, the choline salt according to any one of (1) to (7) or the crystal according to any one of (8) to (12). This specification incorporates the disclosures of Japanese Patent Application No. 2023-081209, from which the present application claims priority.

[0009] According to the present invention, it is possible to provide a salt of a phenanthridinone derivative and a crystal thereof which have an excellent anti-coronavirus effect and excellent solubility.

[0010] Figure 1 shows the PXRD data for Form IV of the choline salt cocrystal, and Figure 2 shows the results of a dog pharmacokinetic study.

[0011] Preferred embodiments of the present invention will now be described in detail.

[0012] As used herein, "alkyl" refers to a straight or branched chain aliphatic hydrocarbon group containing the specified number of carbon atoms. For example, "C1-C8 alkyl" refers to a straight or branched chain saturated hydrocarbon chain containing at least 1 and at most 8 carbon atoms. Suitable alkyls include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.

[0013] As used herein, "alkenyl" refers to a group in which one or more C-C single bonds of the alkyl are replaced with double bonds. Suitable alkenyls include, but are not limited to, vinyl, 1-propenyl, allyl, 1-methylethenyl (isopropenyl), 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-pentenyl, 1-hexenyl, n-heptenyl, 1-octenyl, and the like.

[0014] As used herein, "alkynyl" refers to a group in which one or more C-C single bonds of the alkyl are replaced with a triple bond. Suitable alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl, 1-hexynyl, 1-heptynyl, 1-octynyl, and the like.

[0015] As used herein, "cycloalkyl" refers to an alicyclic alkyl containing a specified number of carbon atoms. For example, a "C3-C6 cycloalkyl" refers to a cyclic hydrocarbon group containing at least 3 and at most 6 carbon atoms. Suitable cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0016] As used herein, "cycloalkenyl" refers to a group in which one or more C--C single bonds of the cycloalkyl are replaced with double bonds. Suitable cycloalkenyls include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, etc.

[0017] As used herein, "cycloalkynyl" refers to a group in which one or more C--C single bonds of the cycloalkyl are replaced with a triple bond. Suitable cycloalkynyl groups include, but are not limited to, cyclobutynyl, cyclopentynyl, cyclohexynyl, and the like.

[0018] As used herein, "heterocyclyl" refers to a group in which one or more carbon atoms of the cycloalkyl, cycloalkenyl, or cycloalkynyl group are each independently substituted with a heteroatom selected from nitrogen (N), sulfur (S), and oxygen (O). In this case, substitution by N or S includes substitution by N-oxide, or oxide or dioxide of S, respectively. Suitable heterocyclyl groups include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, and the like.

[0019] As used herein, "aryl" refers to an aromatic ring group having 6 to 15 carbon atoms. Suitable aryls include, but are not limited to, phenyl, naphthyl, anthryl (anthracenyl), and the like.

[0020] As used herein, "arylalkyl" refers to a group in which one hydrogen atom of the alkyl is substituted with the aryl. Suitable arylalkyl includes, but is not limited to, benzyl, 1-phenethyl, 2-phenethyl, etc.

[0021] As used herein, "arylalkenyl" refers to a group in which one hydrogen atom of the alkenyl is substituted with the aryl. Suitable arylalkenyls include, but are not limited to, styryl and the like.

[0022] As used herein, "heteroaryl" refers to an aryl group in which one or more carbon atoms are each independently substituted with a heteroatom selected from nitrogen (N), sulfur (S), and oxygen (O). In this case, substitution by N or S includes substitution by N-oxide or oxide or dioxide of S, respectively. Suitable heteroaryl groups include, but are not limited to, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, indolyl, and the like.

[0023] As used herein, "heteroarylalkyl" refers to a group in which one of the hydrogen atoms of the alkyl is substituted with the heteroaryl.

[0024] The above-described groups are each independently unsubstituted or substituted with one or more of halogen, hydroxyl, NH, NO, C(O)Z (wherein Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH, or NH-(C1-C8 alkyl)), NH-C(O)Z (wherein Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH, or NH-(C1-C8 alkyl)), N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1 to C8 alkyl, C2 to C8 alkenyl, C2 to C8 alkynyl, C3 to C6 cycloalkyl, C3 to C6 cycloalkenyl, C4 to C6 cycloalkynyl, arylalkyl, or heterocyclyl), C1 to C8 alkyl, C2 to C8 alkenyl, C2 to C8 alkynyl, C3 to C6 cycloalkyl, C3 to C6 cycloalkenyl, C4 to C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl , heteroaryl, heteroarylalkyl, Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl), or Q-(heteroarylalkyl) where Q is O, NH, or S.

[0025] In this specification, "halogen" or "halo" means fluorine, chlorine, bromine or iodine.

[0026] The compound of formula (I) 1 H 2 It may also be a deuterium conversion product converted to H(D).

[0027] The compounds represented by formula (I) also include stereoisomers such as racemates and optically active compounds.

[0028] In the compound of formula (I), R 1 is preferably a C3 to C7 alkyl, more preferably a C4 alkyl, and R 3 is preferably 1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl.

[0029] In the compound of formula (I), R 7 and R 8 at least one of NH2, NH-C(O)Z (wherein Z is C1-C8 alkyl, heterocyclyl, or NH-(C1-C8 alkyl), which groups are unsubstituted or substituted by one or more hydroxyl or NH2), N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1-C8 alkyl or arylalkyl, which groups are unsubstituted or substituted by one or more hydroxyl, O—(C1-C8 alkyl), NH2, N(CH3)2, or CONH2) or NH(R 10 ) (R 10 is C1-C8 alkyl, arylalkyl or heterocyclyl, said groups being unsubstituted or substituted by one or more hydroxyl, O—(C1-C8 alkyl), NH2, N(CH3)2 or CONH2; 8 is NH(R 10 ) (R 10 Further preferred compounds are those in which R is C2-C5 alkyl substituted with one or two hydroxyl groups, e.g., CH2CH2OH, CH2CH(OH)CH2OH, or NH-C(O)Z, where Z is heterocyclyl substituted with one hydroxyl group, e.g., 4-hydroxy-2-pyrrolidinyl.

[0030] Among the compounds represented by formula (I), more specific examples of preferred compounds include the following compounds: (a) R1 is C3-C7 alkyl, R 3 is 1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl, R 2 , R 4 , R 5 , R 6 and R 9 is hydrogen; R 7 and R 8 at least one of NH2, NH-C(O)Z (wherein Z is C1-C8 alkyl, heterocyclyl, or NH-(C1-C8 alkyl), which groups are unsubstituted or substituted by one or more hydroxyl or NH2), N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1-C8 alkyl or arylalkyl, which groups are unsubstituted or substituted by one or more hydroxyl, O—(C1-C8 alkyl), NH2, N(CH3)2, or CONH2) or NH(R 10 ) (R 10 is C1-C8 alkyl, arylalkyl, or heterocyclyl, which groups are unsubstituted or substituted by one or more hydroxyl, O—(C1-C8 alkyl), NH2, N(CH3)2, or CONH2; (b) compounds where R 1 is C3-C7 alkyl, R 3 is 1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl, R 2 , R 4 , R 5 , R 6 , R 7 and R 9 is hydrogen; R 8 is NH(R 10 ) (R 10 is a C2-C5 alkyl substituted with one or two hydroxyl groups, e.g., CH2CH2OH, CH2CH(OH)CH2OH, or NH—C(O)Z, where Z is a heterocyclyl substituted with one hydroxyl group, e.g., 4-hydroxy-2-pyrrolidinyl; (c) compounds where R 1 is C4 alkyl, R3 is 1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl, R 2 , R 4 , R 5 , R 6 and R 9 is hydrogen; R 7 and R 8 at least one of NH2, NH-C(O)Z (wherein Z is C1-C8 alkyl, heterocyclyl, or NH-(C1-C8 alkyl), which groups are unsubstituted or substituted by one or more hydroxyl or NH2), N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1-C8 alkyl or arylalkyl, which groups are unsubstituted or substituted by one or more hydroxyl, O—(C1-C8 alkyl), NH2, N(CH3)2, or CONH2) or NH(R 10 ) (R 10 is C1-C8 alkyl, arylalkyl, or heterocyclyl, which groups are unsubstituted or substituted by one or more hydroxyl, O—(C1-C8 alkyl), NH2, N(CH3)2, or CONH2; (d) compounds where R 1 is C4 alkyl, R 3 is 1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl, R 2 , R 4 , R 5 , R 6 , R 7 and R 9 is hydrogen; R 8 is NH(R 10 ) (R 10 is C2-C5 alkyl substituted with one or two hydroxyl groups, e.g., CH2CH2OH, CH2CH(OH)CH2OH, or NH-C(O)Z, where Z is heterocyclyl substituted with one hydroxyl group, e.g., 4-hydroxy-2-pyrrolidinyl.

[0031] Among the compounds represented by formula (I), specific examples of more preferred compounds include the following compounds: (e) R 1 is C4 alkyl, R 3 is 1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl, R 2 , R 4 , R 5 , R 6 , R 7 and R 9 is hydrogen; R 8 is NH(R 10 ) (R 10 is a C2-C3 alkyl substituted with one or two hydroxyl groups, e.g., CH2CH2OH, CH2CH(OH)CH2OH.

[0032] Among the compounds represented by formula (I), for example, R 1 is C4 alkyl, R 3 is 1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl, R 8 is NH2, R 2 , R 4 , R 5 , R 6 , R 7 and R 9 The compound (NR-31-5) in which is hydrogen can be prepared as follows.

[0033]

[0034] Under an argon atmosphere, a bromine / acetonitrile solution was added dropwise to a solution of compound 10c (NR-31-2) described in Y. Nishiyama, et al., Bioorganic & Medicinal Chemistry 22 (2014) 2799-2808 under ice cooling. After stirring at room temperature, diisopropylethylamine was added dropwise under ice cooling, followed by the addition of p-nitrobenzoyl chloride, and the reaction was allowed to proceed at room temperature. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with saturated brine, dried over sodium sulfate, and the desiccant was filtered off. The filtrate was concentrated, and the resulting residue was added with an aqueous solution of tetrahydrofuran and lithium hydroxide monohydrate. The mixture was then allowed to react at room temperature to obtain the N-(p-nitrobenzoyl)-substituted compound (NR-31-3). Under an argon atmosphere, the N-(p-nitrobenzoyl)-substituted compound is dissolved in N,N-dimethylacetamide, and cesium carbonate, palladium(II) acetate, and tricyclohexylphosphine tetrafluoroborate are added in that order. The mixture is heated and stirred to give the 9-nitrophenanthridinone derivative (NR-31-4). Under an argon atmosphere, the 9-nitrophenanthridinone derivative is dissolved in methanol, palladium-carbon is added, hydrogen is substituted, and the mixture is allowed to react at room temperature to give the 9-aminophenanthridinone derivative (NR-31-5). The 9-aminophenanthridinone derivative (NR-31-5) can be converted to various N-substituted compounds by modification, such as N-alkylation or N-acylation.

[0035] Alternatively, in the above synthesis process, p-fluorobenzoyl chloride may be used instead of p-nitrobenzoyl chloride to obtain a 9-fluorophenanthridinone derivative, which can then be reacted with an amine compound such as 3-amino-1,2-propanediol to convert it into various N-substituted compounds.

[0036] Furthermore, by using m-nitrobenzoyl chloride instead of p-nitrobenzoyl chloride in the above synthesis process, an 8-aminophenanthridinone derivative can be obtained, which can be converted to various N-substituted derivatives by modification such as N-alkylation or N-acylation.

[0037] The obtained product can be purified by a commonly used method, such as column chromatography using silica gel or the like as a carrier, or recrystallization using methanol, ethanol, chloroform, dimethyl sulfoxide, n-hexane-ethyl acetate, water, etc. Examples of elution solvents for column chromatography include methanol, ethanol, chloroform, acetone, hexane, dichloromethane, ethyl acetate, and mixed solvents thereof.

[0038] The choline salt of the present invention can be produced, for example, by mixing the compound represented by formula (I) and choline in ethanol, followed by distilling off the ethanol. Crystals of the choline salt of the present invention can be obtained by adding a good solvent (e.g., ethanol, 1-butanol) and a poor solvent (e.g., n-heptane) to the choline salt thus obtained. The choline salt of the present invention may be a solvate, for example, a hydrate.

[0039] Alternatively, the crystals of the choline salt of the present invention can be produced by dissolving the free form of the compound represented by formula (I) in 1-butanol, adding an aqueous solution of choline, optionally adding seed crystals, and then adding n-heptane to the resulting solution to cause crystallization.

[0040] The choline salt or a crystal thereof of the present invention can be formulated in combination with a conventional pharmaceutical carrier as a pharmaceutical composition for an anti-coronavirus drug, etc. The dosage form is not particularly limited and can be appropriately selected and used as needed, and examples thereof include oral preparations such as tablets, capsules, granules, fine granules, powders, sustained-release preparations, liquids, suspensions, emulsions, syrups, and elixirs, and parenteral preparations such as injections and suppositories.

[0041] Oral preparations are produced by conventional methods using, for example, starch, lactose, sucrose, mannitol, carboxymethylcellulose, inorganic salts, etc. In addition to these, binders, disintegrants, surfactants, lubricants, flow enhancers, flavoring agents, colorants, fragrances, etc. may be added as appropriate.

[0042] Examples of binders include starch, dextrin, gum arabic, gelatin, hydroxypropyl starch, methyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, crystalline cellulose, ethyl cellulose, polyvinylpyrrolidone, and macrogol.

[0043] Examples of disintegrants include starch, hydroxypropyl starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, carboxymethylcellulose, and low-substituted hydroxypropylcellulose.

[0044] Examples of surfactants include sodium lauryl sulfate, soybean lecithin, sucrose fatty acid ester, polysorbate 80, and the like.

[0045] Examples of lubricants include talc, waxes, hydrogenated vegetable oil, sucrose fatty acid ester, magnesium stearate, calcium stearate, aluminum stearate, polyethylene glycol, and the like.

[0046] Examples of the flow promoter include light anhydrous silicic acid, dried aluminum hydroxide gel, synthetic aluminum silicate, magnesium silicate, and the like.

[0047] Injectable preparations are prepared according to conventional methods, and diluents that can be used include, for example, distilled water for injection, physiological saline, aqueous glucose solution, olive oil, sesame oil, peanut oil, soybean oil, corn oil, propylene glycol, and polyethylene glycol. Furthermore, disinfectants, preservatives, stabilizers, isotonicity agents, and soothing agents may be added as needed. From the standpoint of stability, the injectable preparations can be frozen after being filled into vials or the like, and water removed by conventional freeze-drying techniques, followed by reconstitution of the freeze-dried product as a liquid immediately before use. The proportion of the choline salt of the present invention in the injectable preparation can vary between 5 and 50% by weight, but is not limited thereto.

[0048] Other parenteral preparations include suppositories for rectal administration, which are prepared in accordance with conventional methods.

[0049] Formulated anti-coronavirus drugs vary depending on the dosage form, route of administration, etc., but can be administered, for example, 1 to 4 times a day for a period of 1 week to 3 months.

[0050] In order for the oral preparation to exert the desired effect, the dosage will vary depending on the age, weight, and severity of the disease of the patient, but for adults, it is usually appropriate to administer, for example, 0.1 to 6,000 mg, preferably 100 to 2,000 mg, by weight of the choline salt of the present invention, in divided doses several times a day.

[0051] In order for a parenteral preparation to exert the desired effect, it is appropriate to administer, for example, 0.1 to 6,000 mg, preferably 100 to 2,000 mg, by weight of the choline salt of the present invention to an adult, via intravenous injection, intravenous drip infusion, subcutaneous injection, or intramuscular injection, although this will vary depending on the age, weight, and severity of the disease of the patient.

[0052] The anti-coronavirus drug of the present invention exhibits antiviral activity against coronaviruses that cause COVID-19, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), etc., and is used for the prevention or treatment of coronavirus infections such as COVID-19, SARS, MERS, etc. In the present invention, treatment also includes prevention of aggravation.

[0053] The choline salts of the present invention can be included as the sole active ingredient in a pharmaceutical composition, or can include other active ingredients.

[0054] The choline salts of the invention may also be used in combination with other drugs effective against coronavirus infections, such as SARS-CoV-2, either administered separately during the course of treatment or combined with the choline salts of the invention in a single dosage form, such as a tablet, intravenous solution, or capsule. Such other drugs include, for example, remdesivir.

[0055] Coronaviruses are known to infect a variety of animals, and SARS-CoV is also known to infect a variety of animals across species barriers. Therefore, the targets of treatment with the anti-coronavirus drug of the present invention are not limited to humans, but also include various animals such as pets (e.g., dogs and cats), pigs, camels, bats, palm civets, tigers, ferrets, golden hamsters, minks, and sparrows.

[0056] The present invention will be explained in more detail below with reference to examples, but the scope of the present invention is not limited to these examples.

[0057] [Example 1] Anti-SARS-CoV-2 Effect (Assay in HEK293T / ACE2 Cells) (1) Cell Viability Determination (Absorbance) HEK293T / ACE2 cells (2 × 10 4 Cells (1000 cells / well) were seeded onto a microplate with 100 μL of cell culture medium. After 24 hours of culture, 50 μL of various drugs diluted to 4 times the final concentration of the drug stock solution was added to each well, and 50 μL of virus solution of SARS-CoV-2 (WK-521) (obtained from the National Institute of Infectious Diseases) was added at a multiplicity of infection (MOI) of 0.1 (infection plate). To the cell plate, 50 μL of various drugs diluted to 4 times the final concentration of the drug stock solution was added to each well, and 50 μL of cell culture medium was added. After 3 days of culture, the culture supernatant from the infection plate was transferred to a new plate and stored at -80°C. 110 μL of the culture medium from the cell plate was discarded, and 10 μL of Cell Counting Kit-8 was added. 2 After culturing in an incubator for 2 hours, measurements were made at 450 nm (620 nm).

[0058] (2) qPCR measurement of viral RNA in culture supernatant. 50 μL of DNA / RNA Shield (Zymo Research) was added to 50 μL of culture supernatant, and RNA was extracted (15 μL) using the Quick-RNA Viral 96 kit (Zymo Research) according to the manufacturer's instructions. The extracted RNA was diluted 10-fold with nuclease-free water and used as the RNA sample. The RNA sample was then purified using High-Capacity RNA-to-cDNA PCR. TM cDNA was synthesized using a kit (Thermo Fisher Scientific) (Table 1). qPCR measurements were performed under the conditions shown in Table 2.

[0059]

[0060]

[0061] The evaluation results of the anti-SARS-CoV-2 effects of various phenanthridinone derivatives are shown in Table 3.

[0062] IC 50 : 50% inhibitory concentration (concentration of drug that reduces virus production and replication by 50%) IC 90 : 90% inhibitory concentration (the concentration of the drug that reduces virus production and replication by 90%) CC 50 : 50% toxic concentration (the concentration of the drug that reduces the number of viable cells by 50%)

[0063] In Table 3, IC 50 and IC 90 indicates the qPCR measurement results, and CC 50 indicates the results of cell viability determination (absorbance).

[0064] Table 3 shows that the phenanthridinone derivatives have anti-SARS-CoV-2 effects.

[0065] Example 2: Anti-SARS-CoV effect The IC was performed in the same manner as in Example 1, except that SARS-CoV (SARS-CoV-HKU-39849) was used instead of SARS-CoV-2. 50 and IC 90 The results of evaluating the anti-SARS-CoV effects of various phenanthridinone derivatives are shown in Table 4.

[0066]

[0067] [Example 3] Anti-MERS-CoV effect In the same manner as in Example 1, except that MERS-CoV (MERS-CoV-EMC / 2012) was used instead of SARS-CoV-2, IC 50 and IC 90 The results of evaluating the anti-MERS-CoV effects of various phenanthridinone derivatives are shown in Table 5.

[0068]

[0069] [Example 4] Anti-SARS-CoV-2 (mutant strain) effect (assay using VeroE6 / TMPRESS2 cells) VeroE6 / TMPRSS2 cells, which are highly susceptible to SARS-CoV-2, were seeded on a microplate (2 x 10 4After 24 hours of incubation, 50 μL of NR-31, prepared by diluting the drug stock solution to 4 times the final concentration, was added to each well. Furthermore, 50 μL of each SARS-CoV-2 mutant strain (obtained from the National Institute of Infectious Diseases) was added at a multiplicity of infection (MOI) of 0.01, and the cells were incubated at 37°C for 3 days. After incubation, 110 μL of the culture supernatant was discarded, and 10 μL of Cell Counting Kit-8 (Dojindo Laboratories, Inc.) (a viable cell counting kit using the water-soluble tetrazolium salt WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt) as a colorimetric reagent) was added. After 2 hours of incubation, 100 μL of 2-propanol hydrochloride was added and mixed thoroughly. The supernatant was transferred to a new microplate, and the absorbance of each well was measured at 450 / 620 nm. The anti-SARS-CoV-2 efficacy and cytotoxicity of the drug were determined by comparing the viable cell counts of infected and uninfected cells with those without the drug. The results of the evaluation of the efficacy of NR-31 against each SARS-CoV-2 strain are shown in Table 6.

[0070] EC 50 : 50% effective concentration (the concentration of the drug that inhibits cell death induced by SARS-CoV-2 infection by 50%) CC 50 : 50% toxic concentration (the concentration of the drug that reduces the number of viable cells by 50%)

[0071] Example 5 Anti-SARS-CoV-2 Effect of the Choline Salt of the Present Invention (Assay in HEK293T / ACE2 Cells) Of the phenanthridinone derivatives represented by formula (I), NR-31, which showed the most excellent effect in Example 1, was selected as a representative phenanthridinone derivative, and a choline salt of NR-31 was prepared. The anti-SARS-CoV-2 effect of NR-31 and its choline salt (NR-31 choline) was evaluated in the same manner as in Example 1, except that the conditions for qPCR measurement shown in Table 2 were changed as shown in Table 7 below. The results for NR-31 are shown in Table 8, and the results for its choline salt (NR-31 choline) are shown in Table 9.

[0072]

[0073]

[0074]

[0075] [Example 6] Preparation of various salts and co-crystals and investigation of solubility Among the phenanthridinone derivatives represented by formula (I), NR-31, which showed the most excellent effect in Example 1, was selected as a representative phenanthridinone derivative, and the preparation of salts and co-crystals and investigation of solubility were carried out for the choline salt and other salts.

[0076] (1) Preparation of salts and co-crystals <When the second component (coformer) is liquid> (a) Search for crystallization conditions for NR-31-coformer mixtures. An ethanol solution of NR-31 and each coformer was prepared and dispensed into a 96-well plate. After concentrating and drying, a good solvent and a poor solvent were added to the precipitated solid to obtain a small amount of crystals. (b) Scaling up the crystallization conditions. The coformer solution was added to 100 mg of NR-31, and after making a solution with a good solvent, a poor solvent was gradually added. After adding the crystals obtained in (a) as seed crystals, a solid precipitated.

[0077] <When the second component is solid> (a) Preparation of seed crystals of NR-31-coformer mixture: 20 mg of NR-31, each coformer (1 eq.), and 10 μL of each solvent (ethyl acetate, THF, acetone, methanol, acetonitrile) were charged and ground at room temperature using a ball mill. The ground sample was subjected to powder X-ray diffraction measurement (PXRD) to confirm the change in crystal form.

[0078] (b) Scale-up preparation of NR-31-coformer mixture 1 eq. of coformer was added to 100 mg of NR-31, and a solvent was added to form a slurry. The seed crystals obtained in (a) were then added and stirred. The solid obtained by centrifugal filtration was dried under reduced pressure at room temperature, and then analyzed by PXRD and 1 The quality was confirmed by H NMR.

[0079] (2) Solubility study Each form of NR-31 (3 mg) was placed in a solvent (30 mL) and vigorously shaken for 30 seconds every 5 minutes at room temperature (20±5°C). The degree of dissolution was confirmed within 30 minutes. Solvents: Water for injection, JP1 (first fluid for dissolution test, pH 1.2), JP2 (second fluid for dissolution test).

[0080] The results of the preparation and solubility study of various salts and co-crystals are shown in Table 10.

[0081]

[0082] When choline was used as the coformer (second component), salts or cocrystals were formed, but when other components were used as the coformer (second component), salts or cocrystals were not formed. Furthermore, choline salt cocrystals exhibited polymorphism.

[0083] Example 7: Investigation of crystalline polymorphism of choline salt cocrystal The solubility of each polymorphism of the choline salt cocrystal of NR-31 was confirmed according to the method described in the Japanese Pharmacopoeia, and the solubility was confirmed by appearance. As a result, Form I, Form IV, and Form XII were investigated multiple times, and all of them showed good solubility. The results are shown in Table 11.

[0084]

[0085] Example 8: NR-31 Choline Salt Production Method 500 mg of NR-31 and 5 mL of 1-butanol were placed in a flask and heated to 80°C to dissolve the NR-31. After cooling to 50°C, 260 μL of a 50% aqueous choline solution was added. The mixture was then cooled to room temperature, and 1 mg of seed crystals was added. Next, when crystals began to precipitate, 2 mL of n-heptane was added dropwise over 30 minutes. After the dropwise addition, the mixture was cooled to 0°C in an ice bath, and after 30 minutes, it was filtered under reduced pressure using a Kiriyama funnel (Kiriyama filter paper No. 5c) to obtain 442 mg of NR-31 choline salt crystals (Form IV). PXRD data for Form IV, a choline salt cocrystal, is shown in Figure 1. The top line in Figure 1 represents a sample of Form IV of the choline salt cocrystal, the second line from the top represents the dried product (NR-31 choline salt), and the bottom line represents a sample of the slurry taken during crystallization. Figure 1 shows that powder X-ray diffraction analysis reveals five peaks at 8.8, 14.6, 19.6, 23.8, and 27.0 with respect to 2θ±0.2.

[0086] The NMR data of the choline salt cocrystal is shown below. 1 H-NMR (DMSO-d6, 500MHz) δ; 9.06 (1H, s), 7.93 (1H, d, J = 8.5 Hz), 7.76 (2H, d, J = 8.5 Hz), 7.40-7.28 (3H, m), around 6.85 (2H, m), 4.35 (n-BuOH), 4.24 (2H, t, J= 6.0 Hz), 3.84 (2H, s), 3.68 (2H, s), 3.39 (2H, br t), 3.28 (2H, m, overlapped with water peak), 3.12 (9H, s), 1.62 (2H, quin, J = 7.5 Hz), 1.40 (2H, sext, J = 7.5 Hz), 1.40 (n-BuOH), 1.30 (n-BuOH), 0.94 (3H, t, J = 7.5 Hz), 0.86 (n-BuOH).

[0087] [Example 9] Investigation of thermal behavior of choline salt, etc. Thermal analysis was carried out on the free form, DMSO solvate, and choline salt of NR-31 to confirm their thermal behavior, such as melting. The results are shown in Table 12.

[0088]

[0089] Example 10 Pharmacokinetic Study in Dogs (Comparative Study of Salt and Free Form) The NR-31 choline salt crystals (Form IV) obtained in Example 8 and capsules of NR-31 free form were prepared, and a pharmacokinetic study was conducted on 8-month-old male beagle dogs (2 dogs) at a dose of 100 mg / kg. The results are shown in Figure 2. Figure 2 shows that capsules of NR-31 choline salt crystals (Form IV) showed a blood concentration approximately 10 times higher than capsules of NR-31 free form. The phenanthridinone derivative was synthesized as follows.

[0090] (Synthesis Example 1) Synthesis of NR-31-5 (1) Synthesis of NR-31-3

[0091] Under an argon atmosphere, NR-31-2 (78.5 g, 249 mmol) was charged in acetonitrile (393 mL). A solution of bromine (41.8 g, 262 mmol) in acetonitrile (79.0 mL) was added dropwise under ice cooling, and the mixture was stirred at room temperature for 1 hour. Diisopropylethylamine (89.0 mL, 511 mmol) was added dropwise under ice cooling, followed by the addition of p-nitrobenzoyl chloride (106 g, 573 mmol) in portions. The mixture was stirred at room temperature for 15 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over sodium sulfate. The drying agent was removed by filtration, and the filtrate was concentrated. Tetrahydrofuran (315 mL) and an aqueous solution of lithium hydroxide monohydrate (31.4 g, 748 mmol) (185 mL) were added to the residue, and the mixture was stirred at room temperature for 2 hours. The pH was adjusted to 4 using hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate water and saturated brine in that order and dried over sodium sulfate. The drying agent was filtered off and the filtrate was concentrated. The residue was purified to obtain NR-31-3 (97.5 g). (Yield: 72%)

[0092] (2) Synthesis of NR-31-4

[0093] Under an argon atmosphere, NR-31-3 (97.5 g, 179 mmol) was charged into N,N-dimethylacetamide (1.43 L). Cesium carbonate (263 g, 808 mmol), palladium(II) acetate (8.06 g, 35.9 mmol), and tricyclohexylphosphine tetrafluoroborate (16.5 g, 44.9 mmol) were added to the reaction mixture, in that order, and the mixture was stirred at 100 °C for 45 minutes. The mixture was cooled to room temperature and filtered through Celite. The filtrate was poured into tap water, adjusted to pH 4-5 with hydrochloric acid, and extracted with ethyl acetate / heptane. The organic layer was washed with tap water and saturated brine, and then dried over sodium sulfate. The desiccant was filtered off, and the filtrate was concentrated. The residue was purified to give NR-31-4 (57.4 g) (yield: 69%).

[0094] (3) Synthesis of NR-31-5

[0095] Under an argon atmosphere, NR-31-4 (57.4 g, 124 mmol) was charged into methanol (859 mL). 5% palladium-carbon (26.4 g, 12.4 mmol, 50% wet) was added to the reaction mixture, and the system was purged with hydrogen and stirred at room temperature for 6 hours. The mixture was then filtered through Celite, and the filtrate was concentrated. The residue was purified to give NR-31-5 (49.6 g). (Yield: 92%)

[0096] (Synthesis Example 2) Synthesis of NR-31

[0097] Under an argon atmosphere, NR-31-5 (25.0 g, 57.8 mmol) was charged into acetonitrile (501 mL) and dimethyl sulfoxide (62.5 mL). Glycolaldehyde dimer (6.25 g, 52.0 mmol) and sodium triacetoxyborohydride (22.1 g, 104 mmol) were added to the reaction mixture, and the mixture was stirred at room temperature for 21 hours. The solvent was evaporated, and tap water, ethyl acetate, and heptane were added to the residue. The aqueous layer was extracted with ethyl acetate, and the organic layer was washed with tap water and saturated brine, successively. The organic layer was dried over sodium sulfate, and the desiccant was removed by filtration. The filtrate was concentrated. The residue was purified to give NR-31 (15.7 g).

[0098] 1 H-NMR (400MHz, CD3OD): δ= 8.57 (d, 1H, J = 2.0 Hz), 8.08 (d, 1H, J = 8.8 Hz), 7.77 (d, 1H, J = 8.8 Hz), 7.52 (d, 1H, J = 8.8 Hz), 7.29 (d, 1H, J= 2.0 Hz), 6.87 (dd, 1H, J = 8.8, 2.0 Hz), 4.27-4.31 (m, 2H), 3.71 and 3.34 (each 2H, t, J = 6.0 Hz), 1.70-1.62 (2H, m), 1.46-1.37 (2H, m), 0.92 (3H, t, J = 7.4 Hz)

[0099] (Synthesis Example 3) Synthesis of NR-30

[0100] NR-31-5 was condensed with 1-(tert-butoxycarbonyl)-trans-4-(tert-butyldimethylsilyloxy)-L-proline in N,N-dimethylformamide in the presence of HATU and diisopropylethylamine. The reaction mixture was added to water, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed successively with tap water and saturated saline. The organic layer was dried over sodium sulfate, the desiccant was removed by filtration, and the filtrate was concentrated. The residue was dissolved in cyclopentyl methyl ether and treated with hydrochloric acid for deprotection. The reaction mixture was neutralized with saturated aqueous sodium bicarbonate, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed successively with tap water and saturated saline. The organic layer was dried over sodium sulfate, the desiccant was removed by filtration, and the filtrate was concentrated. NR-30 was obtained by purifying the residue.

[0101] 1 ​​H-NMR (400MHz, CD3OD): δ= 8.89 (d, 1H, J = 2.0 Hz), 8.74 (s, 1H), 8.38 (d, 1H, J = 8.8 Hz), 7.94 (d, 1H, J = 8.8 Hz), 7.83 (dd, 1H, J = 2.0, 8.8 Hz), 7.68 (d, 1H, J = 8.8 Hz), 4.41-4.45 (m, 3H), 4.11 (t, 1H, J = 8.4 Hz), 3.13 (dd, 1H, J = 6.0, 2.0Hz), 2.97-3.00 (m, 1H), 2.25-2.30 (m, 1H), 2.00-2.05 (m, 1H), 1.74-1.82 (m, 2H), 1.48-1.57 (m, 2H), 1.02 (t, 3H, J = 7.4 Hz)

[0102] (Synthesis Example 4) Synthesis of NR-16

[0103] NR-31-5 and isobutyryl chloride were reacted with dichloromethane and N,N-diisopropylethylamine in the presence of methanol and potassium carbonate to obtain NR-16.

[0104] (Synthesis Example 5) Synthesis of NR-90

[0105] A 9-fluorophenanthridinone derivative was obtained in the same manner as in Synthesis Example 1 (2) NR-31-4, except that an N-(p-fluorobenzoyl)-substituted derivative was used instead of the N-(p-nitrobenzoyl)-substituted derivative (NR-31-3). Then, 3-amino-1,2-propanediol was reacted with NR-90 in dimethyl sulfoxide at 100°C.

[0106] 1 ​H-NMR (400MHz, CD3OD): δ=8.68 (d, 1H, J = 2.0 Hz), 8.17 (d, 1H, J = 8.8 Hz), 7.87(d, 1H, J = 8.8 Hz), 7.61 (d, 1H, J = 8.8 Hz), 7.41 (s, 1H), 6.99 (dd, 1H, J = 2.0, 8.8 Hz), 4.37-4.41 (m, 2H), 3.88-3.94 (m, 1H), 3.60-3.68 (m, 2H), 3.47-3.52 (dd, 1H, J = 5.2, 13.2 Hz), 3.27-3.35 (m, 1H), 1.72-1.79 (m, 2H), 1.48-1.56 (m, 2H), 1.02 (t, 3H, J = 7.4 Hz)

[0107] (Synthesis Example 6) Other compounds listed in Table 3 were synthesized according to Synthesis Examples 1 to 5. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety.

Claims

1. Formula (I): [In the formula, R 1 is C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl, heteroaryl, and heteroarylalkyl, each of which is independently unsubstituted or substituted with one or more of halogen, hydroxyl, NH2, NO2, C(O)Z, where Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2, or NH-(C1-C8 alkyl); R is selected from alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl) or Q-(heteroarylalkyl), where Q is O, NH or S; 2 ~R 9 are each independently hydrogen, halogen, hydroxyl, NH2, NO2, OSO3H, C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2, or NH-(C1-C8 alkyl)), NH-C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2 or NH-(C1-C8 alkyl)), NH-C(NH)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2 or NH-(C1-C8 alkyl)), N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, arylalkyl, or heterocyclyl), NH(R 10 ) (R 10 is C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, arylalkyl, or heterocyclyl), Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl), and Q-(heteroarylalkyl) (Q is O, NH, or S), as well as C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl , aryl, arylalkyl, arylalkenyl, heteroaryl and heteroarylalkyl, each of which is independently unsubstituted or substituted with one or more of halogen, hydroxyl, NH, NO, C(O)Z, where Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH, or NH-(C1-C8 alkyl), NH-C(O)Z, where Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH, or NH-(C1-C8 alkyl), N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, arylalkyl or heterocyclyl), C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl, heteroaryl Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl) or Q-(heteroarylalkyl), where Q is O, NH or S; 2 ~R 5 any two of the above together with the carbon atoms on the phenanthridine ring to which they are attached form a cycloalkyl, heterocyclyl, or aryl fused to the phenanthridine ring (each of the cycloalkyl, heterocyclyl, or aryl fused to the phenanthridine ring is independently unsubstituted or substituted with one or more of halogen, hydroxyl, NH2, NO2, C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2, or NH-(C1-C8 alkyl)), C1-C8 alkyl, C2-C 8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl) or Q-(heteroarylalkyl) (Q is O, NH or S); 7 and R 8 At least one of the above is NH2, NH-C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2, or NH-(C1-C8 alkyl)), NH-C(NH)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2, or NH-(C1-C8 alkyl)), N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, arylalkyl, or heterocyclyl) or NH(R 10 ) (R 10 is C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, arylalkyl, or heterocyclyl, each of which is independently unsubstituted or substituted with one or more of halogen, hydroxyl, NH2, C(O)Z, where Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkynyl, C4-C6 cycloalkynyl, arylalkyl, or heterocyclyl. C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2 or NH-(C1-C8 alkyl)), NH-C(O)Z (Z is hydrogen, hydroxyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, NH2 or NH-(C1-C8 alkyl)), N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, arylalkyl or heterocyclyl), C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, C4-C6 cycloalkynyl, heterocyclyl, aryl, arylalkyl, arylalkenyl , heteroaryl, heteroarylalkyl, Q-(C1-C8 alkyl), Q-(C2-C8 alkenyl), Q-(C2-C8 alkynyl), Q-(C3-C6 cycloalkyl), Q-(C3-C6 cycloalkenyl), Q-(C4-C6 cycloalkynyl), Q-(heterocyclyl), Q-(aryl), Q-(arylalkyl), Q-(heteroaryl) or Q-(heteroarylalkyl) (Q is substituted with O, NH or S).

2. R 7 and R 8 at least one of is selected from the group consisting of NH2, NH-C(O)Z, where Z is C1-C8 alkyl, heterocyclyl, or NH-(C1-C8 alkyl), which is unsubstituted or substituted by one or more hydroxyls or NH2, N(R 10 )(R 11 ) (R 10 and R 11 are each independently C1-C8 alkyl or arylalkyl, which are unsubstituted or substituted by one or more hydroxyl, O-(C1-C8 alkyl), NH2, N(CH3)2, or CONH2) or NH(R 10 ) (R 10 2. The choline salt of claim 1, wherein: is C1-C8 alkyl, arylalkyl, or heterocyclyl, said groups being unsubstituted or substituted by one or more hydroxyl, O-(C1-C8 alkyl), NH2, N(CH3)2, or CONH2.

3. R 8 NH(R 10 ) (R 10 2. The choline salt of claim 1, wherein Z is C2-C5 alkyl substituted with one or two hydroxyls, or NH-C(O)Z, wherein Z is heterocyclyl substituted with one hydroxyl.

4. R 1 The choline salt of claim 1, wherein is a C3 to C7 alkyl.

5. R 1 The choline salt of claim 1, wherein is a C4 alkyl.

6. R 3 2. The choline salt of claim 1, wherein is 1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl.

7. Formula: A choline salt of the compound represented by the formula:

8. A crystal of the choline salt according to any one of claims 1 to 7.

9. The crystal according to claim 8, which has at least three peaks selected from 8.8, 14.6, 19.6, 23.8 and 27.0 at 2θ±0.2 in powder X-ray diffraction.

10. The crystal according to claim 8, which exhibits an onset of melting at 210±1° C. or 216±1° C. by differential scanning calorimetry.

11. The crystal according to claim 8, which is crystalline form I, IV or XII.

12. The crystal according to claim 11, wherein crystalline form XII is a hydrate.

13. A method for producing the crystals according to claim 8, comprising the steps of dissolving the choline salt according to any one of claims 1 to 7 in ethanol or 1-butanol, and adding n-heptane to the resulting solution to cause crystallization.

14. A method for producing the crystals according to claim 8, comprising the steps of dissolving the free form of the compound represented by formula (I) according to claim 1 in 1-butanol, adding an aqueous solution of choline, and adding n-heptane to the resulting solution to crystallize.

15. A pharmaceutical composition comprising the choline salt or a crystal thereof according to any one of claims 1 to 7 as an active ingredient.

16. An anti-coronavirus drug comprising the choline salt or a crystal thereof according to any one of claims 1 to 7 as an active ingredient.

Citation Information

Patent Citations

  • Crystalline salts of potent HCV inhibitors

    JP2013522221A

  • Choline salt forms of HIV capsid inhibitors

    JP2020531429A

  • Therapeutic agent for hepatitis c

    WO2011093483A1

  • Anti-SARS-cov-2 durg

    WO2021235392A1

  • Anti-sars-cov-2 drug

    WO2023085432A1